Non-small cell lung cancer, HER2-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Page editor Section editor
Singhi Eric.jpeg
Eric K. Singhi, MD
MD Anderson Cancer Center
Houston, TX

Social-twitter-icon.png esinghimd
Amit Kulkarni.jpg
Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN

Social-twitter-icon.png AmitKulkarniMD

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

1 regimens on this page
2 variants on this page


Guidelines

ASCO

Metastatic disease, all lines of therapy

Trastuzumab deruxtecan monotherapy

Regimen variant #1, 5.4 mg/kg

FDA-recommended dose
Study Years of enrollment Evidence
Awaiting publication (DESTINY-Lung02) 2021-ongoing Phase 2 (RT)

Biomarker eligibility criteria

  • HER2 mutations

Antibody-drug conjugate therapy

21-day cycles

Regimen variant #2, 6.4 mg/kg

Study Years of enrollment Evidence
Li et al. 2021 (DESTINY-Lung01) 2018-2020 Phase 2
Awaiting publication (DESTINY-Lung02) 2021-ongoing Phase 2

Biomarker eligibility criteria

  • HER2 mutations

Antibody-drug conjugate therapy

21-day cycles

References

  1. DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains dosing details in manuscript PubMed NCT03505710
  2. DESTINY-Lung02: NCT04644237